Member Info for paternostpauper

Porky’s guiding principle:

"I just can't abide negativity, can't stand it at any level. I can kind of get it if it’s to put off investors to try and get a cheaper price, I don't agree with the practice, but I get it." (posted by Porky - 30/10/21)

Porky - An ethically bankrupt hypocrite, with the moral backbone of a jellyfish in a blender.

His paymaster, Nick (Viera) is a trader and uses Porky’s agenda for his own aims. Although it’s distasteful to many, Nick will post according to his prevailing position and normally only posts on Val, believing big money to be made. Very telling, when he holds several positions elsewhere.

The next few weeks should certainly prove interesting. Personally, I’m looking forward to them immensely.

GLA, DYOR

Some more entertaining 4D posts:

23th May ’22 - “Frankly I'm sick of @Sang and his conspiracy ideas and 24/7 de-ramping campaign. Yesterday 12/4 I posted 4 times. Sang on the other hand posted 19 times. YES 19 dam times to de-ramp here and claims he doesn't hold stock. Go figure.”

25th May ’22 – “Oh F me, the harbinger of doom has just shown up with his negative pearls of wisdom…

No doubt return to his 30 posts of b@llocks about why he wouldn't invest here, why he sold out and why he feels the constant f'cking need to keep telling us this.”

7th June ’22 – “Bloody sick of idiots like @Masterblast here that still think it’s a great use of their time to knock biotech's such as 4D trying to find cures for some of life's most serious issues.”

Even in 4D’s death throes Porky was ramping his dead duck, as he did Harland & Wolff ...same result - administration! How many gullible punters did Porky suck in to both?

I know from Uncanny’s recent responses that the pink fella has been up to his old tricks. Why such venom towards Val? Well, he was a major holder here and sold-up only to lose it all in 4D where his ramping knew no bounds:

21st Apr ’22 - “I have stock at numerous price points from 80p, 60p 55p and including big blocks at 36p and 39p… It’s called investing, not trading”

5th May ’22 – “I am not going to explain again why this stock is materially undervalued and worth a few quid a share. You are either trying to support a short or just out for plain mischief, either way it’s pathetic.”

11th May ’22 – “You are right @Sang. You are not fanatical about shares that you invest in. You are fanatical about de-ramping shares you are NOT invested in.”

It didn’t end well. 4D suspended trading on 24th June, ’22. Shares now worth 0.00p.

Porky despises Valirx because unbelievably, he blames Val for his own investment decision to put all his money into 4D. It will haunt him till his dying day. He now spends his days on here, rocking back and forth while repeating the same garbage like a porcine pink parrot.

3 green posts, undoubtedly by uninvested nomarks. Also, another Nick S post telling us how crap Val is - yet this trader spends hours dishing the same BS. Would almost make you think he has an agenda.

Doesn’t seem to be stopping buyers seeing through him.

Not long till you can action those warrants, Nick. LOL

GLA, DYOR

An RNS packed with positivity and good news, with a sprinkling of income to boot!

What’s not to like?

Happy days

Correction RNS dated 24/9/24

Interesting update from one of our capability partners, Ignota yesterday. They announced the $300k acquisition of Kronos’s clinical assets, a company once valued at $3.5 billion after its IPO. However, it failed to progress its assets past Phase 2 trials and subsequently ceased operations.

Ignota Labs uses its AI platform, SAFEPATH, to identify the root causes of safety issues and improve safety while maintaining therapeutic effectiveness. Ignota’s process will now assess the Kronos assets to identify the issue, solve the causes of toxicity, and develop the drug clinically and commercially.

Relevance to Val? – Well in the RNS of 24/9/25: “Ignota Labs will be entitled to analyse Inaphaea's Biobank data to develop or improve in-silico models which will support sourcing of new onocology assets with the intention of co-developing these assets using Inaphaea's services and Ignota Labs' in-silico platform. The in-silico models will also be used for future services offered by Ignota Labs. Any revenues generated from the co-developed assets or services will be shared between Ignota Labs and ValiRx, subject to a further revenue-sharing agreement to be agreed upon.

Mark added “This agreement leverages the data sets from Inaphaea's biobank to further develop Ignota Labs' in-silico capabilities which will benefit our early-stage evaluation as well as providing an exciting new AI approach to asset discovery."

Sounds like Ignota are faring pretty well and since they are using Inaphaea’s PDCs, well…work it out!

AIMO DYOR GLA

Green is the colour of envy – my screen’s environmentally friendly! LOL

PS Mark’s latest Linkedin post has been ‘liked’ by Charles Chen, Senior Scientist at AstraZeneca.

Mind you, as co-inventor of CLX001, he will be watching developments very keenly.

“Sitting in LAX waiting for my flight home and reflecting on another highly productive business development visit.”

Mark’s opening sentence in his latest Linkedin post.

He has been presenting at the Oxford Global alongside 23 senior executives and scientists from top-tier global pharma companies and wealthy US universities including: Ionis Pharma ($9.4B mkt cap),Regeneron ($77B mkt cap), Lumen Bioscience Inc. ($5.1B mkt cap), Johnson & Johnson ($427B mkt cap), AbbVie ($372 mkt cap), chiesi farmaceutici (c€3 billion net worth), Alnylam Pharma ($59B mkt cap), Camurus ($43B mkt cap), Merck & Co. ($210B mkt cap), and Novartis Pharma ($245B mkt cap).

Two other themes are running simultaneously at the centre; Formulation & Delivery and Biologics. Speakers include directors and professors from Amgen ($155B), Pfizer (139B), Eli Lilly (565B) and Genentech (part of Roche- $245B),

In addition to this who’s who of Biopharma, there are also eminent professors, Deans and Directors from Harvard (2), St John’s, Purdue and Northeastern Universities. Unlike the UK where funding is limited, many US universities are very wealthy. Harvard tops the list with a $52B endowment in FY2024.

Since his appointment, our CEO has emphasised his focus is on those compounds/activities which can be monetised early and seeking EARLY PARTNERING. “ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company”. (RNS 1/9/25)“

In view of the standard of presenters and attendees at this event, it would reasonable to assume more than a few fireside chats have taken place involving little old Valirx.

“ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company”. (RNS 1/9/25)

Some naysayers have suggested this is still a long way down the line - a bold presumption. Most people have heard of NDAs where the relevant commercial information is sensitive. However, in scientific fields there also exists CDAs (Confidential Disclosure Agreements) when discussing experimental compounds, trial designs, or unpublished data —especially with academic or clinical partners. A CDA creates a safe zone for scientific dialogue before formal partnership terms are locked. It allows both parties to share unpublished data, trial designs, or compound profiles without fear of IP leakage.

Initiating a CDA shows the parties are ready to engage beyond surface-level interest. Once in place, parties can selectively share assay data, co-develop end-points, and agree on operational strategies, prior to actual contractual commitments. A potential partner may want early access to shape development or co-own downstream rights. Any deal would likely be tiered, with contingent milestones based on data progress, IND-enabling studies, or clinical entry. However, as SW (Uncanny) has already suggested the deal potential is breathtaking.

Cheers Nick. I'll take that as a compliment. Nice to know my efforts are appreciated.

Always worth understanding the company you have invested in.

So who are Solitek? – Based in Spain, possibly the final piece in the CLX jigsaw. Final decisions have still to be made around formulation and drug delivery with some evaluations centred around this eg. Omios and Altus, as is much PDC screening. Solitek could help Inaphaea shape CLX001 into a medicine ready for patients. Formulation determines the best form of the molecule and designing how it’s made, so influences manufacturing, shelf life, and cost, critical for scaling and commercial success.

A great drug can’t help patients if it doesn’t dissolve, absorb, or stay stable. Formulation affects how fast and how well the drug works and is how a promising molecule is transformed into a usable medicine. It’s the process of designing the right form—like a pill, capsule, virus or injection—so the drug can be safely and effectively delivered to the body.

The molecule is the vehicle. Formulation is the satnav—mapping the fastest, safest and most practical route to the therapeutic destination. Along with the pending patents, once a final formulation has been decided, CLX is ready for partnering.

"First day’s a wrap. Networking dinner to follow. Great series of talks focussed on various aspects of drug development and, importantly, drug delivery. Made some very good connections round the exhibit hall. New ideas and opportunities going forward."

Mark’s latest Linkedin post:

“And we’re off. Day one of Oxford Global’s Discovery and Development meeting in (always) sunny San Diego. Thanks for the invitation to present and the opportunity to showcase VALIRX PLC’s JV Cytolytix and, in particular, aspects of formulation for Clx-001.

Arrived at 17.00 yesterday (1am in my head) and was straight in to a meeting with Louise Phillips and Victor M. Diaz Perez at Solitek - Solid Technologies SL

Looking forward to a great couple of days.”

What do you reckon, Nick? 70-80%+ of Val shares now off the market?

Makes it tough for a trader trying to make a few quid, particularly with the spread.

If you genuinely believe a discounted placing is coming, sit back and relax!

Not a chance. Can’t afford to wait, can you?

You’ve had your day here Nick – accept it and move on.

@ Uncanny – Good factual post but maybe bin the naysayers as I have done, since they have zero to contribute and are generally clueless.

The San Diego event starting Thursday is an incredible stage for Mark to present CLX to the global Pharma elite. Perhaps an opportunity to further the ongoing discussions? Mark has already confirmed further Cytolytix patents are being finalised and it is likely that is the key to an early deal. Once patents are granted, it signals to potential external partners that: a) the IP is legally protected, b) the invention is technically credible and c) it has commercial potential. From that point, early partnering is on the table.

Only earlier this month Mark posted “Excellent strategy day focussed on deal making at Mills & Reeve office in Cambridge. Very insightful and I got to lead the discussion group on how to do an early deal with Pharma.”

Doesn’t take much to read between the lines. Exciting times!

GLA, DYOR, AIMO

6 green bars and counting.

It’s like being back on a Dublin pub crawl. LOL

Meanwhile, Mark is preparing to present CLX in front of the Biopharma elite in just a few days. Maybe come back to gloat following bad news, not just hoping for it.

Clowns!

GLA, AIMO, DYOR, KMA

When Mark E first took the wheel, Val was sluggish, expensive to maintain, and running on empty. It had potential—but needed a full rebuild. Over the past 12 months, he’s stripped it down (diagnosed failings), replaced worn components (built his own elite team), reinforced the chassis (progressed static legacy assets), polished the bodywork (made attractive to LT holders), and turbo-charged the engine (upgrading the biobank/ data and embedding AI tech).

Valirx is the strategic gearbox: licensing, reformulating, and setting the route ahead. Inaphaea, the data-fuelled engine block: powered by multiple capability partners to enable screening, 3D modelling, and validation at speed. The Smart Oncology Engine isn’t just fast—it’s sleek. Val and Inaphaea have shed unnecessary weight through disciplined cost control, streamlined operations, and discarding unproductive parts. The advanced cat converter is particularly cutting-edge. It processes many bio-pharma emissions and refines them into viable, productive oncology compounds with commercial potential (repurposing).

The key to success is a compact but highly-skilled support team working behind the scenes as a single unit. Cross-functional, and deeply specialised, they ensure the smooth running of the Val machine. A precision-calibrated satnav in the form of the new Advisory Board has been installed to ensure no opportunity is missed, no turn misjudged, and every relevant waypoint locked in. “No toll roads” was programmed in from the outset.

After a year of strategic rebuilding, the supercharged Valirx is rolling out of the garage and onto the global stage. It is being showcased at international bio-events and conventions for close inspection by the pharma elite searching for high-performance models with exceptional potential. This isn’t a test drive: Valirx is ready to accelerate, partner, and perform.

GLA, DYOR,AIMO

Any forward-thinking CEO will recognise that AI is no longer optional—it’s essential. The integration of comp models enables faster, more precise, and less resource-intensive testing at a fraction of traditional costs. Val has already capitalised on this through its collaborations with ScreenIn3D and VoxCell, and the new partnership with TwinEdge Bio takes that capability to the next level. By digitising PDC models into “avatars,” Val enables in-silico trials that deliver predictive data in days, not months.

The Dominion update exemplifies asset leverage—repurposing drugs with existing safety data to fast-track, by prioritising hits based on unmet need, patent freedom, and market demand. Mark aims to flip the top 10 potential candidates quickly, and TwinEdge can predict how multiple variables would impact the repurposed drugs. It may be that success for some is via reformulation or minor chemistry—whether via altered dosing (freq or size), delivery mechanisms, or perhaps administered via an oncolytic virus (Omios?). TwinEdge’s AI accelerates this process dramatically, compressing timelines and cost while enhancing value. It exemplifies how Inaphea’s data-rich biobank, comp platforms, and targeted selection criteria can streamline the path from discovery to monetisation.

35% of 'transformative' drugs approved by the FDA are repurposed. Even the notorious thalidomide found a new use as a treatment for leprosy and later for multiple myeloma. It doesn’t need to be major chemistry mods either. Everolimus, originally designated for oncology use, is now FDA-approved as a treatment for epilepsy, simply by modifying the dosage.

Using AI opens the door to exploring synergistic combos—where a repurposed drug may be most effective when paired with another agent or compound, such as CLX. To fully harness comp and 3D modelling, access to high-quality human tissue is essential. The Inaphaea/Dominion alliance already has the raw materials to ”mine” in an ever-increasing PDC biobank. Today’s agreement with Nott’m NHS Trust marks a major step forward, expanding access to ethically consented, clinically annotated samples to power both internal programs and external projects.

Evaluations are not always about immediate income. In June, Mark said Val’s biggest opportunity would come from SPVs by adding value to existing assets and much of the company’s focus is now on SPV prep. Capability partners are already having a significant impact on both the VAL201 and CLX packages. Both Omios (onco virus) and Altus (SmartCelle) formulations present different potential means of administration, while Voxcell’s 3D culture platform is focussed on generating valuable efficacy and tumour penetration data from the impact of CLX on triple neg PDC models. Today represents another significant step in Valirx’s evolution – even if its full impact won’t be recognised until the momentum is already unstoppable.